ASCO GU 2026

Encouraging new data in Prostate cancer

Combination is the way to go - but how to select?

Prolonged PSA declines with normalization of…

Neoadjuvant therapy after molecular biopsy testing

Patient Preferences for ARPI vs ADT in nmHSPC: A Global…

EZH2 oral molecule to enhance ARPI

T-Cell-Engager

Radium-223 + Enzalutamid

Precision medicine for prostate cancer

PSA-dynamics in TALAPRO-2

T-cell engager - first in human

New Mode of Action in mCRPC

Actinium radioligand therapy

Early SBRT shows safety, no added benefit

Adjuvant therapy for RCC: Progress made, key questions…

New second-line option in mRCC

Belzutifan + Lenvatinib: A New Second-Line Approach in…

Real World Data - RCC

Long‑term effects of adjuvant therapy

HIF based combination are here to stay

Upcoming new standard for adjuvant RCC

Adjuvant Pembrolizumab + Belzutifan vs Pembrolizumab

Treatment after immunotherapy in aRCC: always a complex…

Advances in the Adjuvant Treatment of RCC

Combination therapy in adjuvant RCC

New follow-up therapy with lenvatinib + belzutifan

Equilibrar eficacia y toxicidad: el desafío en el ccRCC…

The future is bright, but complex

Closing the gap for platin eligibility

BCG plus CPI for NMIBC - do the benefits outweigh the…

Perioperative EV+Pembrolizumab in MIBC

Promising data - how to stratify the patients for the…

Perioperative EV + P - the new standard?!

A new class of drug in luminal UC

Urinary ctDNA vs. plasma ctDNA

Rethinking the use of HER2neu in routine clinical…

MIBC - time for a historic paradigm shift?

EV+P new SOC in MIBC

ctDNA from plasma and urine in MIBC

pCR in MIBC under EV + P

ctDNA dynamics in the IMvigor011 trial

New perioperative standard for MIBC

New machanism of action in pts with UC

Une nouvelle classe de médicaments pour le carcinome…

Dinámica del ctDNA en el ensayo IMvigor011

Cáncer de vejiga músculo-invasivo: ¿es hora de un…